AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 05/04/22

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Tony DiMeo – Head-Investor Relations Chirag Patel – President and Co-Chief Executive Officer Chintu Patel – Co-Chief Executive Officer Tasos Konidaris –...

Amneal Pharma (NYSE:AMRX -12.6%) stock falls after the company posted lower-than-expected Q1 result, hurt by loss of exclusivity of Zomig Nasal Spray. Revenue for the quarter increased 1% Y/Y to $498M, but missed estimates by $4.66M. Adjusted EBITDA in the quarter was $100M, down 13% com...

Amneal Pharmaceuticals press release (NYSE:AMRX): Q1 Non-GAAP EPS of $0.12 misses by $0.01. Revenue of $497.63M (+0.9% Y/Y) misses by $4.66M. FY22 Guidance: Net revenue of $2.15B-$2.25B vs consensus of $2.19B; Adj EPS of $0.80-$0.85 vs consensus of $0.84 For further details see: Amneal ...

‒ Q1 2022 Net Revenue of $498 million; GAAP Net Loss of $2 million; Diluted Loss per Share of $(0.01) ‒ ‒ Adjusted EBITDA (1) of $100 million includes $5 million of R&D milestone expense; Adjusted Diluted EPS (1) of $0.12 ‒ &...

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $0.13 (-35.0% Y/Y) and the consensus Revenue Estimate is $502.29M (+1.9% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 88% of t...

Amneal Pharmaceuticals (NYSE:AMRX) on Wednesday announced U.S. Food and Drug Administration (FDA) approval for the company's biologics license application for bevacizumab-maly, a biosimilar of Swiss drugmaker Roche Holding's cancer drug Avastin. The company said the biosimilar will be ma...

- Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Com...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern T...

Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018. That's due to a merger with Impax which led to heavy losses but also gave the company the opportunity to gain access to the public markets. After the founders stepped away for most of the troub...